FLVCR1-AS1 and FBXL19-AS1: Two Putative lncRNA Candidates in Multiple Human Cancers

Abstract

(1) Background: Mounting evidence supports the idea that one of the most critical agents in controlling gene expression could be long non-coding RNAs (lncRNAs). Upregulation of lncRNA is observed in the different processes related to pathologies, such as tumor occurrence and development. Among the crescent number of lncRNAs discovered, FLVCR1-AS1 and FBXL19-AS1 have been identified as oncogenes in many cancer progression and prognosis types, including cholangiocarcinoma, gastric cancer, glioma and glioblastoma, hepatocellular carcinoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, and osteosarcoma. Therefore, abnormal FBXL19-AS1 and FLVCR1-AS1 expression affect a variety of cellular activities, including metastasis, aggressiveness, and proliferation; (2) Methods: This study was searched via PubMed and Google Scholar databases until May 2022; (3) Results: FLVCR1-AS1 and FBXL19-AS1 participate in tumorigenesis and have an active role in impacting several signaling pathways that regulate cell proliferation, migration, invasion, metastasis, and EMT; (4) Conclusions: Our review focuses on the possible molecular mechanisms in a variety of cancers regulated by FLVCR1-AS1 and FBXL19-AS1. It is not surprising that there has been significant interest in the possibility that these lncRNAs might be used as biomarkers for diagnosis or as a target to improve a broader range of cancers in the future.

Identifying metastatic biomarkers of colorectal cancer: Machine learning modeling and experimental validation

“…Incorporating biomarkers alongside imaging methods can signi cantly enhance the accuracy of detecting CRC liver metastasis [8]. Various biomarkers are utilized for detecting CRC liver metastasis, including but not limited to CEA, CA19-9, CA125, and others [9,10]. On the other hand, while serum markers such as CEA are helpful in diagnosing CRC, their limitations in terms of sensitivity and speci city decrease their reliability in identifying hepatic metastases particularly [6].…”

Identification and validation of a seven cuproptosis-associated lncRNA signature to predict the prognosis of endometrial cancer

“…6,7 Many researches have shown relationships between lncRNAs and tumor occurrence and development, metastasis, drug resistance, the immune microenvironment, diagnosis, and prognosis, and have identified them as potential therapeutic targets and diagnostic biomarkers. [7][8][9][10][11][12] Several studies have constructed gene signatures based on lncRNAs to predict the prognosis of cancer patients. For instance, Pan et al constructed a lncRNA signature based on cancer-associated fibroblasts, which could predict the prognosis of patients with colorectal cancer, as well as other pan-cancers.…”